Myovant Sciences Ltd (MYOV)

Trade MYOV now with
11/19/2019 7:34:18 AM Myovant Sciences Phase3 HERO Study Of Relugolix Meets Primary Efficacy Endpoint
10/10/2019 8:34:32 AM Myovant Sciences Announces Presentation Of Phase 3 LIBERTY 1 & 2 Study Results At ASRM Scientific Congress
8/20/2019 8:34:28 AM Myovant Sciences Completes Patient Recruitment For Phase 3 SPIRIT 2 Study Of Relugolix Combination Therapy
5/14/2019 7:37:56 AM Myovant Sciences Announces Positive Phase 3 Results From LIBERTY 1 Study Evaluating Relugolix Combination Therapy
10/24/2018 8:35:31 AM Myovant Sciences Completes Enrollment In Phase 3 HERO Trial Of Relugolix In Men With Advanced Prostate Cancer
10/8/2018 8:37:47 AM Myovant Sciences And Flo Health Partner To Develop Digital Tool To Screen Women For Heavy Menstrual Bleeding
7/11/2018 4:08:34 PM Myovant Sciences Announces $75 Mln Public Offering Of Common Shares
7/10/2018 7:13:37 AM Myovant Sciences Completes Screening For Phase 3 LIBERTY 1 Study Evaluating Relugolix In Women With Uterine Fibroids
6/7/2018 4:14:23 PM Myovant Sciences Q4 Loss/share $0.81 Vs. Loss $0.37 Year Ago
4/20/2018 8:02:32 AM Myovant Sciences And PERIOD Launch Partnership